Publicaciones en colaboración con investigadores/as de Erasmus University Medical Center (67)

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

2021

  1. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  2. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

    Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 680-690

2019

  1. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

2018

  1. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

    JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397

2017

  1. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560

  2. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

  3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

  4. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Blood, Vol. 127, Núm. 25, pp. 3165-3174

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

  2. Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors

    Annals of Oncology, Vol. 26, Núm. 11, pp. 2247-2256

  3. Global myeloma research clusters, output, and citations: A bibliometric mapping and clustering analysis

    PLoS ONE, Vol. 10, Núm. 1

  4. Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 2, pp. 63-67

  5. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 9, pp. 519-530

2014

  1. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362

  2. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

  3. European perspective on multiple myeloma treatment strategies in 2014

    Oncologist, Vol. 19, Núm. 8, pp. 829-844

  4. IMWG consensus on risk stratification in multiple myeloma

    Leukemia, Vol. 28, Núm. 2, pp. 269-277